SAN FRANCISCO--(BUSINESS WIRE)--Cannabis Science Inc. (NASD OTCBB: CBIS), an emerging pharmaceutical cannabis company, announced today that patent filings are expected for two of its key innovations. “The Drug Development Team members recognize the importance of having our first cannabis-based medicine covered, not just by one patent, but by two,” Dr. Mary J. Ruwart, Vice President, Research & Development explained. “A competitor can sometimes engineer a way around a single patent. Patenting both the manufacturing process as well as the delivery system virtually guarantees that our product will be immune to ‘invasion’ by a competing company.”
